Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Tumor Infiltrating Lymphocytes and Chemotherapy with or without Immunotherapy in Treating Patients with Metastatic Melanoma

Trial Status: administratively complete

This early phase I trial studies the side effects and how well tumor infiltrating lymphocytes and chemotherapy with or without immunotherapy work in treating patients with melanoma that has spread to other places in the body (metastatic). Specific cells, such as tumor infiltrating lymphocytes developed from the immune cells found within a patient's tumor masses may help to target tumor cells. Drugs used in chemotherapy, such as cyclophosphamide and fludarabine phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the tumor, and may interfere with the ability of tumor cells to grow and spread. Giving tumor infiltrating lymphocyte and chemotherapy with or without immunotherapy may work better in treating patients with melanoma.